Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMtoGo trial of temocillin versus standard of care for asymptomatic gonorrhea
2025-524475-23-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gonorrhea comparing Temocillin arm, Ceftriaxone standard-of-care arm and Standard-of-care comparator arm (3 arms). Primary endpoint: Therapeutic success at day 21. Planned start May 2026; status: authorised.
02
Drugs
temocillinceftriaxone
03
Conditions
gonorrhea
Beyond the preview
Go deeper on 2025-524475-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524475-23-00.